2023-2024

CHBRP generally analyzes introduced bills prior to their first Senate or Assembly Health Committee hearing. Completed CHBRP analyses (and the analyzed bill language) are available at http://chbrp.org/analysis/completed-analyses. As bills move through the Legislature, bills may be significantly amended, which may alter CHBRP’s projected impacts. The table, below, indicates the current version of each analyzed bill and the extent to which CHBRP’s analyses remain relevant. Current bill language and the bill status are available at http://leginfo.legislature.ca.gov/.

CHBRP’s analyses may still be of use after the legislative cycle concludes in order to inform future legislation, the implementation of analyzed legislation that is signed into law or included in California’s budget, and the ongoing evaluation of relevant health benefit mandates and repeals.

The below is current as of 4/16/2024. 

Bill Current location Bill amended since CHBRP analysis? Which portions of CHBRP’s analysis remain relevant?
AB 85
(Weber): Social Determinants of Health: Screening and Outreach
Vetoed by the Governor - 10/07/23 Yes – 9/08/2023 All portions of CHBRP’s analysis remain relevant. Amended language would expand which health care professionals health plans/policies are required to provide information about access to, and could lead to more enrollees gaining access to these professionals and receiving services they otherwise would not have. Additionally, implementation of AB 85 would be delayed until 2026, with a report from the working group submitted in 2027. Language has also been added specifying reimbursement rates for FQHCs.
AB 620
(Connolly): Metabolic Disorders
Vetoed by the Governor - 10/07/23 Yes – 9/08/2023 All portions of CHBRP’s analysis remain relevant; however, the utilization and cost impacts may decrease due to amended bill language excluding coverage for special food products for people with chronic digestive disorders. Amended language delays the implementation date by six months to July 1, 2024.
AB 716
(Boerner Horvath): Emergency Ground Medical Transportation
Approved by the Governor - 10/08/23 Yes – 9/6/2023 All portions of CHBRP’s analysis remain relevant.
AB 874
(Weber): Out-of-pocket Expenses
Assembly Health committee hearing postponed - 04/21/23 No All portions of CHBRP’s analysis remain relevant.
AB 907
(Lowenthal): Coverage for PANDAS and PANS
Vetoed by the Governor - 10/07/23 Yes – 7/03/2023 All portions of CHBRP’s analysis remain relevant.
AB 1048
(Wicks): Dental Benefits and Rate Review
Approved by the Governor - 10/08/23 Yes – 9/8/2023 All portions of CHBRP’s analysis remain relevant, however, the fiscal impacts have been reduced due to the removal of prohibitions of waiting periods and preexisting conditions for dental plan products in the individual and small group markets. In addition, implementation is now delayed to 1/1/2025 vs 1/1/2024.
AB 1060
(Ortega): Naloxone Hydrochloride
Vetoed by the Governor - 10/07/23 Yes – 9/8/2023 All portions of CHBRP’s updated analysis published June 23, 2023, remain relevant.
AB 1157
(Ortega): Rehabilitative and Habilitative Services: Durable Medical Equipment and Services
Held under submission in the Senate - 09/01/23 Yes – 7/13/2023 Amended language would require the California Secretary of Health and Human Services to seek ways of implementing this mandate that would not exceed Essential Health Benefits in California. All portions of CHBRP’s analysis remain relevant.
AB 1288
(Reyes): Medication-Assisted Treatment
Vetoed by the Governor - 10/08/23 Yes – 7/13/2023 All portions of CHBRP’s analysis remain relevant. For commercial/CalPERS enrollees, amended language would additionally prohibit the application of prior authorization or step therapy requirements to the coverage of naloxone products or another opioid antagonist approved by the United States Food and Drug Administration (FDA). An emergency intervention, opioid antagonists are used when an overdose appears to be occurring and naloxone is broadly distributed (without cost) by multiple organizations seeking to decrease overdose deaths and is available over-the-counter (without a prescription). As neither step therapy nor prior authorization requirements are likely to be applied to an emergency-use medication that is broadly available without cost, the additional prohibitions are unlikely to have a measurable impact.
AB 1451
(Jackson): Behavioral Health Crisis Treatment
Vetoed by the Governor - 10/07/23 Yes – 7/13/2023 All portions of CHBRP’s analysis remain relevant.
AB 1645
(Zbur): Cost Sharing
Vetoed by the Governor - 10/07/23 Yes – 7/13/2023 Amended language would, for small group and individual market plans and policies, delay the implementation of some requirements by 12 months. Amended language requires reimbursement of nonparticipating essential community providers at either the plan/insurer’s average contracted rate or 125% of the amount Medicare reimburses, whichever is greater. The inclusion of the rate related to Medicare and the requirement of using whichever is greater would result in some increased reimbursements, which would increase the impact on total expenditures from $20,065,000 to $23,237,000. All other portions of CHBRP’s analysis remain relevant.
AB 2028
(Ortega) Medical Loss Ratio
View status on https://leginfo.legislature.ca.gov/ No All portions of CHBRP’s analysis remain relevant.
AB 2180
(Weber) Cost Sharing
View status on https://leginfo.legislature.ca.gov/ Yes – 4/30/2024 All portions of CHBRP’s analysis remain relevant. Amended language broadens the definition of “third-party patient assistance program,” which expands the scope of the bill to include financial assistance from for-profit entities. As a result, the estimated total net annual expenditures would be higher. Amended language also adds several reporting requirements for state regulators and state-regulated health plans insurers, as well as a 10-year sunset to the bill’s provision, none of which would alter CHBRP’s estimated fiscal projections.
AB 2467
(Bauer-Kahan) Menopause
View status on https://leginfo.legislature.ca.gov/ Yes – 5/20/2024 The impacts on utilization and expenditures would be somewhat lower than projected, as the bill would no longer require coverage for compounded bioidentical hormones, which are not approved by the Food and Drug Administration (FDA). However, there would still be impacts, as the bill would still require coverage for multiple FDA-approved drugs, including manufactured bioidentical hormones. All other portions of CHBRP’s analysis remain relevant..
AB 2668
(Berman) Cranial Prostheses
View status on https://leginfo.legislature.ca.gov/ No All portions of CHBRP’s analysis remain relevant.
AB 2843
(Petrie-Norris) Rape and Sexual Assault
View status on https://leginfo.legislature.ca.gov/ No All portions of CHBRP’s analysis remain relevant.
AB 3059
(Weber) Human Milk
View status on https://leginfo.legislature.ca.gov/ No All portions of CHBRP’s analysis remain relevant.
AB 3245
(Patterson) Colorectal Cancer Screening
View status on https://leginfo.legislature.ca.gov/ Yes – 6/10/2024 All portions of CHBRP’s analysis remain relevant.
SB 70
(Wiener): Prescription Drug Coverage
Held under submission in Assembly Health Committee - 09/01/23 Yes – 6/29/2023 All portions of CHBRP’s analysis remain relevant.
SB 90
(Wiener): Insulin Affordability
Vetoed by the Governor - 10/07/23 Yes– 9/6/2023 Amended language delays implementation in the small group and individual markets until 2025. All portions of CHBRP’s analysis remain relevant. 2025. Additionally, for individual and small group plans and policies, cost sharing limits are only applicable to insulin products covered under Tiers 1 and 2. It is possible this amended language would result in higher cost sharing for some portion of enrollees whose insulin is covered under a higher tier.
SB 339
(Wiener): HIV Preexposure Prophylaxis and Postexposure Prophylaxis
Approved by the Governor - 2/6/24 Yes – 1/8/2024 Amended language would strike requirement for pharmacist services to be reimbursed at 100% of the fee schedule for physician services and instead require reimbursement for pharmacist services performed at in-network pharmacies and out-of-network pharmacies if the plan/insurer has an out-of-network pharmacy benefit. Estimated fiscal impacts may be reduced due to potentially lower reimbursement rates. All other portions of CHBRP’s analysis remain relevant.
SB 427
(Portantino): Antiretroviral Drugs, Devices, and Products
View status on https://leginfo.legislature.ca.gov/ Yes – 4/4/2024 All portions of CHBRP’s analysis remain relevant. Amended language exempts the insurance of Medi-Cal beneficiaries in plansplans regulated by the Department of Managed Health Care, and delays implementation of the bill for the individual and small group until January 1, 2026.
SB 621
(Caballero): Biosimilar Drugs
Approved by the Governor - 10/08/23 Yes – 5/02/2023 All portions of CHBRP’s analysis remain relevant.
SB 635
(Menjivar and Portantino): Hearing Aids
Vetoed by the Governor - 10/07/23 Yes – 9/8/2023 All portions of CHBRP’s analysis (which was based on June 8th amended language) remain relevant. The July 13th amendment delays implementation until 2025. The bill was amended on 9/8/2023 to exclude Medi-Cal, however existing coverage already exists in Medi-Cal and thus did not impact CHBRP’s fiscal projections.
SB 694
(Eggman) Medi-Cal: Self-Measured Blood Pressure Devices and Services
Vetoed by the Governor - 10/07/23 Yes – 9/01/2023 All portions of CHBRP’s analysis remain relevant.
SB 729
(Menjivar): Treatment for Infertility and Fertility Services
Hearing postponed by Assembly Health committee - 09/01/23 Yes – 8/14/2023 Amended language would require coverage of fertility services for large group plans and policies, and would require small group plans and policies to offer coverage for fertility services. Amended language specifies fertility services includes a maximum of three completed oocyte retrievals, and also adds an exemption for religious employers. Scenario 2 remains relevant, although impacts would likely be reduced marginally due to the exemption for religious employers.
SB 839
(Bradford) Obesity Parity Act
January 10 set for first hearing canceled at the request of author. No All portions of CHBRP’s analysis remain relevant. See also CHBRP’s letter regarding SB 1008 (Bradford).
SB 1008
(Bradford) Obesity Parity Act
View status on https://leginfo.legislature.ca.gov/ Yes – 4/29/2024 All portions of CHBRP’s analysis remain relevant.
SB 1180
(Ashby) Emergency Medical Services
View status on https://leginfo.legislature.ca.gov/ Yes – 5/16/2024 All portions of CHBRP’s analysis remain relevant. The number of mobile integrated health programs may increase more than anticipated due to amended bill language (4/29/24) removing the phrase “fire department-based” from the definition of mobile integrated health programs. Most recent amended language (5/16/24) conditions Medi-Cal coverage on an appropriation, receipt of any necessary federal approvals, and the availability of federal financial participation.
SB 1236
(Blakespear) Medicare Supplements
View status on https://leginfo.legislature.ca.gov/ Yes – 4/29/2024 All portions of CHBRP’s analysis remain relevant. As amended, SB 1236 would alter an existing law that addresses Medicare Supplement plans and policies. The existing law, as would SB 1236 requires open enrollment as each beneficiary becomes initially eligible. Additionally, the existing law annually allows enrolled beneficiaries to change Medicare Supplement plans or policies (to one of equal or lesser value) at each beneficiary’s birthday. As amended, SB 1236 would alter the existing law to end the exclusion of beneficiaries with end stage renal disease (ESRD) from these enrollment periods. The proposed changes to the existing law could result in earlier enrollment (by some months) in Medicare Supplement by some beneficiaries with ESRD. However, as the initial version of SB 1236 analyzed by CHBRP (as well as the amended version) would allow such enrollment every January and would not exclude beneficiaries with ESRD, the additional enrollment would be limited and CHBRP would expect no substantive impact differences.